April 28, 2017


Few Clouds On High-Priced, Ultra-Orphan Drug Horizon

By Mary Jo Laffler & Emily Hayes

With BioMarin’s Brineura hitting the market with a $702,000 annual price tag, recent experience for other high-priced rare disease drugs supports the theory that payers will accept high costs for ultra-rare pediatric disease therapies.

read full article >